Flexuspine adds $2.1M to Series B

Pittsburgh's Flexuspine has added $2.1 million from existing investors in a Series B round of funding, according to an SEC filing. The company's CEO, Vincent Jannetty, declined to provide more details to the Pittsburgh Business Times as to how much money the company has raised in the round.

Flexuspine's Functional Spinal Unit (FSU) total spinal segment replacement is designed as an alternative to fusion by re-establishing mobility to an affected segment of the lumbar spine, the company notes on its website. It is eyeing European approval, and this money will be used for pilot studies and to help fund a potential EU launch.

The company has received the FDA's nod to begin a clinical feasibility study of its system. The study has started the trial, but Jannetty wouldn't discuss it further, according to MedCity News.

Flexuspine's investors are Onset Ventures, The Vertical Group and Warburg Pincus, according to the company's website.

- get more from the Pittsburgh Business Times
- see the MedCity News report

Suggested Articles

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.

Cognoa aims to equip pediatricians with an AI-powered app that can spot the signs of autism, allowing them to diagnose in the doctor's office.

Longitude Capital invests in what its founders call “transformative healthcare companies," working in areas they hope will increase quality of life.